Epstein-Barr virus replication in oral hairy leukoplakia: Response, persistence, and resistance to treatment with valacyclovir

Journal of Infectious Diseases

Volumn 188, Issue 6, 2003, Pages 883-890

  Walling, Dennis M ^a   Flaitz, Catherine M ^b   Nichols, C Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALACICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITION KINETICS; LEUKOPLAKIA; MALE; MOLECULAR BIOLOGY; MOUTH MUCOSA; ORAL BIOPSY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; TREATMENT FAILURE; VIRUS REPLICATION; VIRUS RESISTANCE;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; LEUKOPLAKIA, HAIRY; MIDDLE AGED; MOUTH MUCOSA; TREATMENT OUTCOME; VALINE; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0141729383     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378072     Document Type: Article

References (41)

1. Gratama JW, Oosterveer MA, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 1988; 85:8693-6.
2. Gerber P, Lucas S, Nonoyama M, Perlin E, Goldstein LI. Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet 1972; 2:988-9.
3. Miller G, Niederman JC, Andrews LL. Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med 1973; 288:229-32.
4. Reichart PA, Langford A, Gelderblom HR, Pohle HD, Becker J, Wolf H. Oral hairy leukoplakia: observations in 95 cases and review of the literature. J Oral Pathol Med 1989; 18:410-5.
5. Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 1985; 313:1564-71.
6. Resnick L, Herbst JS, Ablashi DV, et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 1988; 259:384-8.
7. Herbst JS, Morgan J, Raab-Traub N, Resnick L. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia. J Am Acad Dermatol 1989; 21:753-6.
8. Greenspan D, De Souza YG, Conant MA, et al. Efficacy of desciclovir in the treatment of Epstein-Barr virus infection in oral hairy leukoplakia. J Acquir Immune Defic Syndr 1990; 3:571-8.
9. Selby P, Powles RL, Blake S, et al. Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir. Lancet 1984; 2:1428-30.
10. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability, and metabolic disposition of valacyclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995; 39:2759-64.
11. Greenspan JS, Greenspan D. Oral hairy leukoplakia: diagnosis and management. Oral Surg Oral Med Oral Pathol 1989; 67:396-403.
12. Greenspan JS, De Souza YG, Regezi JA, et al. Comparison of cytopathic changes in oral hairy leukoplakia with in situ hybridization for EBV DNA. Oral Dis 1998; 4:95-9.
13. Gilligan K, Rajadurai P, Resnick L, Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci USA 1990; 87:8790-4.
14. Walling DM, Shebib N, Weaver SC, Nichols CM, Flaitz CM, Webster-Cyriaque J. The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. J Infect Dis 1999; 179:763-74.
15. Walling DM, Brown AL, Etienne W, Keitle WA, Ling PD. Multiple EBV infections in healthy individuals. J Virol 2003; 77:6546-50.
16. Datta AK, Colby BM, Shaw JE, Pagano JS. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci USA 1980; 77:5163-6.
17. Datta AK, Hood RE. Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid. Virology 1981; 114:52-9.
18. Rickinson AB, Epstein MA. Sensitivity of the transforming and replicative functions of Epstein-Barr virus to inhibition by phosphonoacetate. J Gen Virol 1978; 40:409-20.
19. Ragoczy T, Miller G. Role of the Epstein-Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol 1999; 73:9858-66.
20. Feederle R, Kost M, Baumann M, et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000; 19:3080-9.
21. Cochet C, Martel-Renoir D, Grunewald V, et al. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 1993; 197:358-65.
22. Sam CK, Brooks LA, Niedobitek G, Young LS, Prasad U, Rickinson AB. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 1993; 53:957-62.
23. Hayes DP, Brink AA, Vervoort MB, Middeldorp JM, Meijer CJ, van den Brule AJ. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol Pathol 1999; 52:97-103.
24. Martel-Renoir D, Grunewald V, Touitou R, Schwaab G, Joab I. Qualitative analysis of the expression of Epstein-Barr virus lyric genes in nasopharyngeal carcinoma biopsies. J Gen Virol 1995; 76:1401-8.
25. Heller M, Dambaugh T, Kieff E. Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol 1981; 38:632-48.
26. Lin JC, Shaw JE, Smith MC, Pagano JS. Effect of 12-o-tetradecanoylphorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology 1979; 99:183-7.
27. Lin JC, Smith MC, Pagano JS. Effects of 12-o-tetradecanoyl-phorbol-13-acetate on cell proliferation and Epstein-Barr virus DNA replication. Virology 1982; 117:186-94.
28. Young LS, Lau R, Rowe M, et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 1991; 65:2868-74.
29. Sandvej K, Krenacs L, Hamihon-Dutoit SJ, Rindum JL, Pindborg JJ, Pallesen G. Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia. Histopathology 1992; 20:387-95.
30. Niedobitek G, Young LS, Lau R, et al. Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol 1991; 72:3035-46.
31. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Storthz KA. Persistent productive Epstein-Barr virus replication in normal tongue epithelial cells in vivo. J Infect Dis 2001; 184:1499-1507.
32. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 1996; 87:706-11.
33. Murray PG, Niedobitek G, Kremmer E, et al. In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol 1996; 178:44-7.
34. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 2000; 74:7610-8.
35. Rabanus JP, Greenspan D, Petersen V, Leser U, Wolf H, Greenspan JS. Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia. Am J Pathol 1991; 139:185-97.
36. Field AK, Biron KK. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev 1994; 7:1-13.
37. Walling DM, Edmiston SN, Sixbey JW, Abdel-Hamid M, Resnick L, Raab-Traub N. Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci USA 1992; 89:6560-4.
38. Walling DM, Perkins AG, Webster-Cyriaque J, Resnick L, Raab-Traub N. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and trauscriptional expression. J Virol 1994; 68:7918-26.
39. Walling DM, Raab-Traub N. Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia. J Virol 1994; 68:7909-17.
40. Walling DM, Clark NM, Markovitz DM, et al. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. J Infect Dis 1995; 171:1122-30.
41. Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother 1998; 42:2923-31.